Infliximab - Remicade; cA2; Avakine; tumor necrosis factor monoclonal antibody, recombinant -- Product Record

TNF Mab, rDNA/J&J

    Nomenclature:
      TNF Mab, rDNA/J&J [BIO]
      Remicade [TR]
      Infliximab [FDA USAN INN]
      immunoglobulin G, anti-(human tumor necrosis factor) (human-mouse monoclonal cA2 heavy chain), disulfide with human-mouse monoclonal cA2 light chain, dimer [CAS]
      57894-0030-01 [NDC]
      cA2 [SY]
      chimeric IgG1 anti-human TNF MAb cA2 [SY]
      TNF-alpha MAb cA2 [SY]
      tumor necrosis factor-alpha monoclonal antibody [SY]
      Avakine [TR former [dropped because suggested product was a cytokine]]
      CentTNF [TR former or non-U.S.]

    molecular weight (kDa) = 149

    FDA Class:  Biologic BLA

    Year of approval (FDA) = 1998